Last reviewed · How we verify
NCT04278911: CIACS
Effect of CI on Prognosis in the Elderly Patients With ACS
trial testing MMSE and MoCA in Acute Coronary Syndrome in 500 participants. Status unknown.
1 January 2022
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2020 |
| Primary completion | 1 January 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- MMSE and MoCA
Conditions studied
- Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Elderly — all drugs for Elderly →
Sponsor
Beijing Friendship Hospital
Who can join
65 and older, any sex, with Acute Coronary Syndrome or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the incidence and characteristics of cognitive Impairment(CI) in the elderly patients with acute coronary syndrome (ACS), and to determine whether CI are predictive of the prognosis of major adverse cardiovascular events (MACE) and mortality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04278911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
- NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
- NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04278911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 20 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04278911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing